Hims & Hers Expands Weight Loss Portfolio with Compounded Semaglutide
Event summary
- Hims & Hers is now enabling providers to prescribe compounded Semaglutide pills, a needle-free alternative to Wegovy.
- The introductory price for the compounded Semaglutide pill is $49/month for the first month, increasing to $99/month thereafter.
- Hims & Hers doubled its facility footprint to over one million square feet in 2025, integrating pharmacy, lab testing, and R&D capabilities.
- The compounded drug is not FDA-approved and uses a different formulation and delivery system than oral semaglutide.
The big picture
Hims & Hers’ expansion into compounded semaglutide represents a strategic bet on personalized care and affordability within the rapidly growing weight loss market. The move leverages the company’s significant infrastructure investments but introduces regulatory and competitive risks associated with compounded drugs. This strategy highlights the ongoing trend of telehealth platforms seeking to expand treatment options and disrupt traditional pharmaceutical distribution models.
What we're watching
- Regulatory Scrutiny
- The use of compounded drugs, particularly in a telehealth context, may attract increased scrutiny from the FDA and state regulatory bodies, potentially impacting Hims & Hers’ operational model.
- Pricing Sustainability
- The introductory $49/month price point is likely intended to drive adoption, but the subsequent increase to $99/month could impact customer retention and overall market penetration.
- Competitive Response
- Novo Nordisk and other pharmaceutical companies may accelerate the development of their own needle-free or alternative formulations, potentially eroding Hims & Hers’ competitive advantage in the weight loss market.
Related topics